In the BioHarmony Drug Report Database
Irinotecan
Camptosar, Onivyde, Onivyde pegylated (irinotecan) is a small molecule pharmaceutical. Irinotecan was first approved as Camptosar on 1996-06-14. It is used to treat breast neoplasms, colonic neoplasms, leukemia, lymphoma, and neoplasm metastasis amongst others in the USA. It has been approved in Europe to treat pancreatic neoplasms. The pharmaceutical is active against DNA topoisomerase 1. Camptosar’s patents are valid until 2036-10-15 (FDA).
Trade Name
|
Onivyde pegylated liposomal, known as Onivyde |
|---|---|
Common Name
|
irinotecan |
ChEMBL ID
|
CHEMBL481 |
Indication
|
breast neoplasms, colonic neoplasms, leukemia, lymphoma, neoplasm metastasis, non-small-cell lung carcinoma, pancreatic neoplasms, rectal neoplasms, stomach neoplasms |
Drug Class
|
Antineoplastics (camptothecine derivatives) |
Image (chem structure or protein)